|
Report No. : |
353783 |
|
Report Date : |
17.12.2015 |
IDENTIFICATION DETAILS
|
Name : |
ACTAVIS PHARMA COMPANY |
|
|
|
|
Registered Office : |
6733 Mississauga Road, Ste 400 Mississauga, Ontario L5N 6J5 |
|
|
|
|
Country : |
Canada |
|
|
|
|
Date of Incorporation : |
01.01.2004 |
|
|
|
|
Legal Form : |
N.S. Unlimited Liability |
|
|
|
|
Line of Business : |
Manufactures and sells generic pharmaceuticals. |
|
|
|
|
No. of Employee : |
100+ |
RATING & COMMENTS
|
MIRA’s Rating : |
Aa |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Canada |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CANADA ECONOMIC OVERVIEW
As a high-tech industrial society in the trillion-dollar class, Canada resembles the US in its market-oriented economic system, pattern of production, and high living standards. Since World War II, the impressive growth of the manufacturing, mining, and service sectors has transformed the nation from a largely rural economy into one primarily industrial and urban. The 1989 US-Canada Free Trade Agreement (FTA) and the 1994 North American Free Trade Agreement (NAFTA) (which includes Mexico) touched off a dramatic increase in trade and economic integration with the US, its principal trading partner. Canada enjoys a substantial trade surplus with the US, which absorbs about three-fourths of Canadian merchandise exports each year. Canada is the US's largest foreign supplier of energy, including oil, gas, and electric power, and a top source of US uranium imports. Given its abundant natural resources, highly skilled labor force, and modern capital plant, Canada enjoyed solid economic growth from 1993 through 2007. Buffeted by the global economic crisis, the economy dropped into a sharp recession in the final months of 2008, and Ottawa posted its first fiscal deficit in 2009 after 12 years of surplus. Canada's major banks, however, emerged from the financial crisis of 2008-09 among the strongest in the world, owing to the early intervention by the Bank of Canada and the financial sector's tradition of conservative lending practices and strong capitalization. Canada achieved marginal growth in 2010-14 and plans to balance the budget by 2015 despite the recent drop in oil prices. In addition, the country's petroleum sector is rapidly expanding, because Alberta's oil sands significantly boosted Canada's proven oil reserves. Canada now ranks third in the world in proved oil reserves behind Saudi Arabia and Venezuela and is the world’s fifth-largest oil producer.
|
Source
: CIA |
COBALT
PHARMACEUTICALS INC.
Address: 6500 Kitimat Road, Mississauga,
Ontario L5N 2B8 - Canada
Corporate ID#: NS-3242221
State: Nova Scotia
Judicial form: Corporation – Profit
Date incorporated: 01-01-2004
On 07-23-2013, name changed to:
ACTAVIS PHARMA COMPANY
On 12-27-2013, the Company
merged with:
ACTAVIS PHARMA OTC COMPANY
(ID# 3242228)
TO CREATE:
ACTAVIS PHARMA COMPANY
Incorporated in Nova Scotia
on 32777762
(copy on attachment)
COBALT
PHARMACEUTICALS INC. is no more active.
ACTAVIS PHARMA
COMPANY
Address: 6733 Mississauga Road,
Ste 400
Mississauga,
Ontario L5N 6J5 - Canada
Telephone: +1 905-814-1820
Fax: +1 905-814-8696
Website: www.actavis.ca
Corporate ID#: 3286374
State: Nova
Scotia
Judicial form: N.S. Unlimited
Liability
Date incorporated: 12-30-2014
Date founded: 01-01-2004
Stock: --
Value: --
Name of manager: Jean-Guy
GOULET
History:
Business issued from the
merger of
- ACTAVIS PHARMA COMPANY
(ID# 3277762)
- ACTAVIS CANADA COMPANY
- 3242038 NOVA SCOTIA
COMPANY
on 12-30-2014
Business:
ACTAVIS PHARMA COMPANY manufactures and sells generic pharmaceuticals in
Canada.
The Company had the highest growth rate in prescriptions in the Canadian
market and launched 10 products including Clopidogrel, Levonorgestrel,
Latanoprost and Candesartan.
Additionally, the Company filed 20 applications during the year and
launched a new sales organization in Quebec, which accounts for approximately
22% of the Canadian market.
Staff: 100+
Operations & branches:
At the headquarters, we
find a factory, warehouse and office.
Shareholders:
ACTAVIS INC.
400 Interspace Parkway
Parsippany, NJ 07054 – USA
Actavis, Inc., an integrated specialty pharmaceutical company, focuses
on developing, manufacturing, marketing, and distributing generic, brand, and
biosimilar products primarily in North America, Europe, Asia, the Middle East,
and Africa. It develops and manufactures various molecules and dosage
combinations, including urology and women’s health products; and biosimilars
products in women’s health, oncology, and other therapeutic categories.
The company produces generic, brand, and over the counter pharmaceutical
products in various formulations, including modified release, solid oral
dosage, semi-solids, liquids, gels, transdermal products, and injectables.
It also develops and out-licenses generic pharmaceutical products to
customers; and distributes products for third parties.
The ultimate parent company is:
ALLERGAN PLC
Grand Canal Square, Docklands
Dublin 2, Ireland
The Company is listed with the NYSE under symbol AGN.
Management:
Jean-Guy GOULET, President and Director.
He serves as the Chief Executive Officer and President of RATIOPHARM,
INC.
Mr. Goulet has been the President of North America at Ratiopharm since
2006. He served as the President at Cobalt Pharmaceuticals Company, a
subsidiary of Actavis Plc (formerly, Watson Pharmaceuticals, Inc.). Mr. Goulet
joined Actavis Plc in 2011. He led Actavis' Canada and Latin America business.
He served as Chief Executive Officer and President of Ratiopharm Canada.
Mr. Goulet started his career in the quality control department at
Technilab, which was later acquired by ratiopharm. He rapidly moved up within
the organization, gaining increasing responsibilities in operations, sales,
marketing and business development.
In 2002, he was appointed President of the Commercial division of
Ratiopharm Canada. Mr. Goulet served as a Director of LYRtech Inc. from March
15, 2007 to January 23, 2008. He invested much time and energy in the
development and representation of the Canadian Generic Pharmaceutical
Association as the Chairman of the board of directors from 2002 to 2006 and was
also part of the negotiation team during the federal patent law revisions from
1993 to 2006. Mr. Goulet graduated in Chemistry from Université de Montréal.
Ali MOGHADDAM, Vice President of sales
Kent MAKOR, Vice President of Scientific Affairs
Stephen KAUFHOLD, Vice President and Treasurer
Robert BAILEY, Director and Secretary
Subsidiaries
And partnership: N/A
In Canada, privately held
corporations are not required to publish any financials.
On a direct call, a
financial assistant controlled the present report but deferred any financials.
We sent a fax but no answer
received.
Consolidate revenue 2014:
USD 13,062,300,000=
Net loss: USD 1,630,500,000=
Banks: Royal Bank of Canada
Legal filings
& complaints:
As of today date, there is no legal filing pending with the Courts.
Secured debts summary: None